Why is your research important and how will it influence the understanding and treatment of MS?
Our previous work shows that autologous haematopoietic stem cell transplantation (AHSCT) can induce sustained immune renewal and extensive remodelling of the clonal T-cell repertoire, resulting in durable clinical remission in people with MS. And currently therapies exist which can slow the neurological disability progression, however, do not completely prevent it. Therapies inducing sustained neuroregeneration still remain a landmark goal for MS treatment.
Hence our current project will be early stages of a pilot laboratory study to ascertain whether regulatory immune cells obtained from people with MS are viable cellular therapy agents to induce remyelination. If successful, this preliminary study will be of high clinical relevance for paving the steps towards successful neuroregeneration in MS.